EA201490165A1 - Производные 1-арил-4-метил-[1,2,4]триазоло[4,3-a]хиноксалина - Google Patents

Производные 1-арил-4-метил-[1,2,4]триазоло[4,3-a]хиноксалина

Info

Publication number
EA201490165A1
EA201490165A1 EA201490165A EA201490165A EA201490165A1 EA 201490165 A1 EA201490165 A1 EA 201490165A1 EA 201490165 A EA201490165 A EA 201490165A EA 201490165 A EA201490165 A EA 201490165A EA 201490165 A1 EA201490165 A1 EA 201490165A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
compositions
pde2
relates
present
Prior art date
Application number
EA201490165A
Other languages
English (en)
Other versions
EA027418B1 (ru
Inventor
Хосе Игнасио Андрес-Хиль
Фредерик Ян Рита Ромбаутс
Андрес Авелино Трабанко-Суарес
Грета Констанция Петер Ванхоф
Мери Де Анхелис
Петер Якобус Йоханнес Антониус Бейнстерс
Жером Эмиль Жорж Гийемон
Ги Мориц Р. Борман
Софи Жанн Леопольдин Селен
Мартен Влиген
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201490165A1 publication Critical patent/EA201490165A1/ru
Publication of EA027418B1 publication Critical patent/EA027418B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)

Abstract

Изобретение относится к новым производным 1-арил-4-метил-[1,2,4]триазоло[4,3-а]-хиноксалина в качестве ингибиторов фосфодиэстеразы 2 (PDE2) и в меньшей степени фосфодиэстеразы 10 (PDE10) или в качестве ингибиторов обоих фосфодиэстераз 2 и 10. Настоящее изобретение также направлено на фармацевтические композиции, содержащие такие соединения, способы получения таких соединений и композиций и применение таких соединений и композиций для профилактики и лечения расстройств, в которых участвует PDE2, или расстройств, в которых участвует как PDE2, так и PDE10, таких как неврологические и психиатрические расстройства и эндокринологические заболевания или болезни обмена веществ. Настоящее изобретение также относится к меченным радиоактивным изотопом соединениям, которые могут быть полезны в визуализации и определении количества фермента PDE2 в тканях с применением позитронно-эмиссионной томографии (PET). Настоящее изобретение также направлено на композиции, содержащие такие соединения, способы получения таких соединений и композиций, применение таких соединений и композиций для визуализации ткани, клеток или хозяина,илии на предшественники указанных соединений.
EA201490165A 2011-06-27 2012-06-26 ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ EA027418B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11171519 2011-06-27
PCT/EP2012/062381 WO2013000924A1 (en) 2011-06-27 2012-06-26 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES

Publications (2)

Publication Number Publication Date
EA201490165A1 true EA201490165A1 (ru) 2014-04-30
EA027418B1 EA027418B1 (ru) 2017-07-31

Family

ID=44370665

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490165A EA027418B1 (ru) 2011-06-27 2012-06-26 ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ

Country Status (11)

Country Link
US (1) US10604523B2 (ru)
EP (1) EP2723744B1 (ru)
JP (1) JP6115962B2 (ru)
CN (1) CN103619846B (ru)
AU (1) AU2012277912B2 (ru)
BR (1) BR112013033375B1 (ru)
CA (1) CA2838645C (ru)
EA (1) EA027418B1 (ru)
ES (1) ES2575092T3 (ru)
MX (1) MX344600B (ru)
WO (1) WO2013000924A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
JP2014526453A (ja) * 2011-09-09 2014-10-06 ハー・ルンドベック・アクチエゼルスカベット ピリジン化合物およびそれらの使用
EP2863909B1 (en) * 2012-06-26 2020-11-04 Janssen Pharmaceutica N.V. Combinations comprising 4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline compounds as pde 2 inhibitors and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
JP2016513083A (ja) * 2013-01-31 2016-05-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 放射標識された化合物
WO2014139983A1 (en) 2013-03-13 2014-09-18 H. Lundbeck A/S [1,2,4]triazolo[4,3-a]quinoxalines as dual pde2/pde10 inhibitors
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
NZ725161A (en) 2014-04-23 2017-10-27 Dart Neuroscience (Cayman) Ltd Substituted [1,2,4] triazolo [1,5-a] pyrimidin-7-yl compounds as pde2 inhibitors
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
US10300064B2 (en) 2014-12-06 2019-05-28 Intra-Cellular Therapies, Inc. Organic compounds
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
EP3285581B1 (en) 2015-03-26 2021-08-11 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
WO2016179059A1 (en) 2015-05-05 2016-11-10 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3313852B1 (en) 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
EP3156405A1 (en) 2015-10-13 2017-04-19 Boehringer Ingelheim International GmbH Spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxamide
AU2016348549B2 (en) 2015-11-02 2020-07-23 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
WO2017165311A1 (en) * 2016-03-21 2017-09-28 Perlstein Lab Pbc Fused heterocyclic organic compounds and uses thereof
CN109923116B (zh) 2016-11-02 2022-12-06 詹森药业有限公司 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物
EA039102B1 (ru) * 2016-11-02 2021-12-03 Янссен Фармацевтика Нв Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2
CA3038913A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
CN107827828B (zh) * 2017-11-21 2021-03-30 南京华漫新材料科技有限公司 含苯酰肼骨架的喹喔啉衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111447930A (zh) 2017-11-23 2020-07-24 奥斯陆大学医院公司 心动过速的治疗

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5584421A (en) 1978-12-21 1980-06-25 Mitsui Cokes Kogyo Kk Method of making fibrous carbon
US4242513A (en) 1979-03-05 1980-12-30 Appleton Papers Inc. Lactone compounds containing a heterocyclic radical
WO1986007059A2 (en) 1985-05-25 1986-12-04 Yoshitomi Pharmaceutical Industries, Ltd. Oxodiazine compounds
AU5921890A (en) 1989-06-13 1991-01-08 Smithkline Beecham Corporation Monokine activity interference
AU6355190A (en) 1989-06-13 1991-01-17 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
AU622330B2 (en) 1989-06-23 1992-04-02 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds having a nitrogen atom in the bridgehead for use as fungicides
KR910011852A (ko) 1989-12-04 1991-08-07 폴 디. 매튜카이티스 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물
AU8205991A (en) 1990-06-12 1992-01-07 Smithkline Beecham Corporation Inhibition of 5-lipoxygenase and cyclooxygenase pathway mediated diseases
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
ZA919797B (en) 1990-12-13 1992-10-28 Smithkline Beecham Corp Bicyclo-5,6-dihydro-7h-pyrrolo-1,20-imidazol-7-ols and 7-ones
CA2098177A1 (en) 1990-12-13 1992-06-13 Jerry L. Adams Csaids
US5683998A (en) 1991-04-23 1997-11-04 Toray Industries, Inc. Tricyclic triazolo derivatives, processes for producing the same and the uses of the same
CN1033327C (zh) 1991-04-23 1996-11-20 东丽株式会社 三环三唑并衍生物的制造方法
DK31093D0 (ru) 1993-03-19 1993-03-19 Novo Nordisk As
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
US20010007867A1 (en) 1999-12-13 2001-07-12 Yuhpyng L. Chen Substituted 6,5-hetero-bicyclic derivatives
AU6279598A (en) 1997-02-18 1998-09-08 Neurocrine Biosciences, Inc. Biazacyclic CRF antagonists
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
IL134748A0 (en) 1997-09-02 2001-04-30 Du Pont Pharm Co Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
JP4032566B2 (ja) 1999-06-21 2008-01-16 東レ株式会社 発光素子
JP2001057292A (ja) 1999-08-20 2001-02-27 Toray Ind Inc 発光素子
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
KR20030016222A (ko) 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
US6403588B1 (en) 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
EP1301511A2 (en) 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
WO2002034748A1 (en) 2000-10-24 2002-05-02 Sankyo Company, Limited Imidazopyridine derivatives
AU2002224927A1 (en) 2000-12-13 2002-06-24 Basf Aktiengesellschaft Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ATE416175T1 (de) 2001-02-20 2008-12-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
AU2002258550B2 (en) 2001-03-14 2006-04-27 Eli Lilly And Company Retinoid X receptor modulators
EP1382603B1 (en) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
US6806268B2 (en) 2001-05-30 2004-10-19 Alteon, Inc. Method for treating glaucoma V
EP1406611A2 (en) 2001-05-30 2004-04-14 Alteon, Inc. Method for treating fibrotic diseases or other indications
CN1518550A (zh) 2001-06-21 2004-08-04 ʷ��˿�������ȳ�ķ���޹�˾ 用于预防和治疗疱疹病毒感染的咪唑并[1,2-a]吡啶衍生物
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
US7244740B2 (en) 2001-10-05 2007-07-17 Smithkline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
WO2003061659A1 (en) 2002-01-22 2003-07-31 Merck & Co., Inc. Treating stress response with chemokine receptor ccr5 modulators
ATE346070T1 (de) 2002-03-05 2006-12-15 Lilly Co Eli Purinderivate als kinaseinhibitoren
JP2003313126A (ja) 2002-04-23 2003-11-06 Sankyo Co Ltd イミダゾピリジン誘導体を有効成分とする医薬
JP2004002826A (ja) 2002-04-24 2004-01-08 Sankyo Co Ltd 高分子イミダゾピリジン誘導体
JP2005530788A (ja) 2002-05-13 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類
AU2003237249A1 (en) 2002-05-24 2003-12-12 Isis Pharmaceuticals, Inc. Oligonucleotides having modified nucleoside units
GB0217783D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US20050245520A1 (en) 2002-07-31 2005-11-03 Nerina Dodic 2-Phenylpyridin-4-yl derivatives as alk5 inhibitors
AU2003256297A1 (en) 2002-08-09 2004-02-25 Eli Lilly And Company Benzimidazoles and benzothiazoles as inhibitors of map kinase
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
WO2004022562A1 (en) 2002-09-09 2004-03-18 Cellular Genomics, Inc. 6-ARYL-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF
AU2003267087A1 (en) 2002-09-13 2004-04-30 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
WO2004026867A2 (en) 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
US7576085B2 (en) 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
PE20050081A1 (es) 2002-09-23 2005-03-01 Schering Corp Nuevas imidazopirazinas como inhibidores de cinasas dependientes de ciclinas
JP2006503838A (ja) 2002-09-23 2006-02-02 シェーリング　コーポレイション サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン
WO2004035579A1 (ja) 2002-10-15 2004-04-29 Takeda Pharmaceutical Company Limited イミダゾピリジン誘導体、その製造法および用途
CA2506129C (en) 2002-11-15 2015-02-17 Idenix (Cayman) Limited 2'-branched nucleosides and flaviviridae mutation
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
EP1582516B1 (en) 2003-01-10 2013-07-17 Idemitsu Kosan Co., Ltd. Nitrogenous heterocyclic derivative and organic electroluminescent element employing the same
WO2004072081A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004075846A2 (en) 2003-02-25 2004-09-10 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
US7041671B2 (en) 2003-04-02 2006-05-09 Pfizer Inc Pyrrolo[1,2-b]pyridazine compounds and their uses
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
US20060094699A1 (en) 2003-04-11 2006-05-04 Kampen Gita Camilla T Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy
US20060100235A1 (en) 2003-04-11 2006-05-11 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
WO2004103991A1 (fr) 2003-05-20 2004-12-02 'chemical Diversity Research Institute', Ltd. Piperidines 2-substituees, bibliotheque focalisee et composition pharmaceutique
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
KR100553752B1 (ko) 2003-10-13 2006-02-20 삼성에스디아이 주식회사 이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
EP1682549B1 (en) 2003-10-28 2010-09-22 Sepracor Inc. Imidazo[1,2-a]pyridine anxiolytics
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
EP1713784A1 (en) 2004-02-12 2006-10-25 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
EP1765351B9 (en) 2004-06-09 2010-03-24 Oncalis AG Protein kinase inhibitors
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
EP1790650B1 (en) 2004-08-31 2014-03-26 Msd Kk NEW SUBSTITUTED IMIDAZOLE DERIVATIVES
CA2584248A1 (en) 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
CA2583812A1 (en) 2004-10-28 2006-05-11 Irm Llc Compounds and compositions as hedgehog pathway modulators
US8030327B2 (en) 2004-11-08 2011-10-04 Mds K.K. Fused imidazole derivative
WO2006053121A2 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
US20080207634A1 (en) 2004-12-17 2008-08-28 Kristjan Gudmundsson Chemical Compounds
US20080167314A1 (en) 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
WO2006094235A1 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
US7666880B2 (en) 2005-03-21 2010-02-23 S*Bio Pte Ltd. Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
PL1869049T3 (pl) 2005-03-21 2009-07-31 Lilly Co Eli Związki imidazopirydazyny
JP2008536817A (ja) 2005-03-24 2008-09-11 グラクソ グループ リミテッド 胃腸疾患の処置用医薬として有用なイミダゾ（１，２−ａ）ピリジン誘導体
WO2006107784A1 (en) 2005-04-05 2006-10-12 Eli Lilly And Company Imidazopyridazine compounds
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
GB0513423D0 (en) 2005-06-30 2005-08-03 Glaxo Group Ltd Novel compounds
ES2396671T3 (es) 2005-07-11 2013-02-25 Novartis Ag Derivados de la indolilmaleimida como inhibidores de la proteína quinasa
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
US20070185063A1 (en) 2005-08-23 2007-08-09 Idenix Pharmaceuticals, Inc. Seven-membered ring nucleosides
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2623721C (en) 2005-09-27 2014-05-13 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mglur2 antagonists
US7745428B2 (en) 2005-09-30 2010-06-29 Astrazeneca Ab Imidazo[1,2-A]pyridine having anti-cell-proliferation activity
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
CA2628534A1 (en) 2005-11-10 2007-05-18 Schering Corporation Methods for inhibiting protein kinases
TW200804386A (en) 2005-11-10 2008-01-16 Schering Corp Imidazopyrazines as protein kinase inhibitors
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007087283A2 (en) 2006-01-23 2007-08-02 Vertex Pharmaceuticals Incorporated Thiophene-carboxamides useful as inhibitors of protein kinases
EP1984375A2 (en) 2006-01-25 2008-10-29 Smithkline Beecham Corporation Chemical compounds
US20090203732A1 (en) 2006-03-02 2009-08-13 Dashyant Dhanak Thiazolones for Use as P13 Kinase Inhibitors
WO2007145921A1 (en) 2006-06-06 2007-12-21 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
ITVA20060041A1 (it) 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
EP2044061A2 (en) 2006-07-20 2009-04-08 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
EP2046333A4 (en) 2006-07-24 2010-09-15 Glaxosmithkline Llc THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE
WO2008027812A2 (en) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Imidazopyridine and imidazopyrimidine derivatives
WO2008030795A2 (en) 2006-09-05 2008-03-13 Boards Of Regents, The University Of Texas System Compositions and methods for inhibition of tyrosine kinases
EP2471529A3 (en) 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
AU2007292924A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
MX2009003650A (es) 2006-10-06 2009-04-22 Abbott Lab Nuevos imidazotiazoles e imidazoxazoles.
US7563920B2 (en) 2006-10-30 2009-07-21 Draximage Limited Methods for preparing 2-methoxyisobutylisonitrile and tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
PE20080931A1 (es) 2006-11-08 2008-07-19 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa
US20080221083A1 (en) 2006-11-20 2008-09-11 Matthias Hochgurtel Heterobicyclic metalloprotease inhibitors
US7622584B2 (en) 2006-11-24 2009-11-24 Samsung Mobile Display Co., Ltd. Imidazopyridine-based compound and organic light emitting diode including organic layer comprising the imidazopyridine-based compound
UA96964C2 (ru) 2006-12-04 2011-12-26 Астразенека Аб Соединения полициклической мочевины с антибактериальными свойствами
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
AU2008205642B2 (en) 2007-01-12 2013-06-06 Msd K.K. Spirochromanon derivatives
US20080242862A1 (en) 2007-03-27 2008-10-02 Calderwood David J Novel imidazo based heterocycles
EP2139888A2 (en) 2007-03-28 2010-01-06 Array Biopharma, Inc. Imidazoý1,2-a¨pyridine compounds as receptor tyrosine kinase inhibitors
UA101611C2 (ru) 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
CA2682925A1 (en) 2007-04-10 2008-10-16 David C. Ihle Heteroaryl amide analogues
WO2008133192A1 (ja) 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
JP2010526120A (ja) 2007-05-09 2010-07-29 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としての置換イミダゾピリダジン
ES2393038T3 (es) 2007-05-10 2012-12-18 Biocryst Pharmaceuticals, Inc. Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer
JP5291095B2 (ja) 2007-06-01 2013-09-18 グラクソスミスクライン エルエルシー イミダゾピリジンキナーゼ阻害剤
MX2009013729A (es) 2007-06-14 2010-01-25 Schering Corp Imidazopirazinas como inhibidores de proteina quinasa.
KR101030007B1 (ko) 2007-06-15 2011-04-20 삼성모바일디스플레이주식회사 헤테로방향환 함유 화합물, 이의 제조 방법 및 이를 이용한유기 발광 소자
CA2690192A1 (en) 2007-06-26 2008-12-31 Gilead Colorado, Inc. Imidazopyridinyl thiazolyl histone deacetylase inhibitors
US8188083B2 (en) 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
FR2918061B1 (fr) 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
ATE493386T1 (de) 2007-07-27 2011-01-15 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo-ä3.1.0ü-hexan-derivate
WO2009017701A2 (en) 2007-07-31 2009-02-05 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
US8592591B2 (en) 2007-08-14 2013-11-26 Bayer Intellectual Property Gmbh Fused bicyclic imidazoles
ES2421237T7 (es) 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EP2217601A1 (en) 2007-11-08 2010-08-18 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyridazines for use as protein kinase inhibitors
EP2217069A4 (en) 2007-11-09 2012-03-14 Salk Inst For Biological Studi INHIBITORS OF NON-NUCLEOSIDE INHIBITORS OF THE REVERSE TRANSCRIPTASE
AU2008329775A1 (en) * 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
WO2009077334A1 (en) 2007-12-14 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
AU2008345688A1 (en) 2007-12-21 2009-07-09 Wyeth Llc Imidazo [1,2-b] pyridazine compounds as modulators of liver X receptors
JP5355421B2 (ja) 2007-12-21 2013-11-27 出光興産株式会社 有機エレクトロルミネッセンス素子
WO2009086123A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-a] pyridine compounds
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
WO2009097233A1 (en) 2008-01-28 2009-08-06 Schering Corporation Imidazopyrazines as protein kinase inhibitors
ATE555116T1 (de) 2008-02-26 2012-05-15 Merck Sharp & Dohme Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
WO2009117157A1 (en) 2008-03-20 2009-09-24 Amgen Inc. Aurora kinase modulators and method of use
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
DE102008017853A1 (de) 2008-04-09 2009-10-15 Merck Patent Gmbh Thienopyrimidine
ES2398684T3 (es) 2008-04-23 2013-03-21 Gilead Sciences, Inc. Análogos de carbanucleósido para el tratamiento antiviral
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
JP5774982B2 (ja) 2008-05-19 2015-09-09 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． イミダゾ［１，２−ａ］ピリジン化合物
US20110077248A1 (en) 2008-05-29 2011-03-31 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
WO2010002985A1 (en) 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
WO2010009155A2 (en) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Fused heterocyclyc inhibitor compounds
EP2323665B1 (en) 2008-07-24 2013-06-19 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
FR2934994B1 (fr) 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
US8198449B2 (en) 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20120021519A1 (en) 2008-09-19 2012-01-26 Presidents And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5416944B2 (ja) 2008-10-23 2014-02-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
WO2010054253A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
WO2010059838A2 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Pde4 inhibitors selective for the long form of pde4 for treating inflammation and avoiding side effects
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
AU2009333214B2 (en) * 2008-12-17 2013-09-26 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP5210187B2 (ja) 2009-01-22 2013-06-12 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2400991A1 (en) * 2009-02-24 2012-01-04 Janssen Pharmaceutica, N.V. Radiolabelled pde10 ligands
US8367222B2 (en) 2009-02-27 2013-02-05 Idemitsu Kosan Co., Ltd. Organic electroluminescent device
BRPI1009287A2 (pt) 2009-03-05 2019-09-24 Astellas Pharma Inc composto de quinoxalina
EP2408773A2 (en) 2009-03-20 2012-01-25 Amgen, Inc Inhibitors of pi3 kinase
US8604466B2 (en) 2009-03-24 2013-12-10 Idemitsu Kosan Co., Ltd. Organic electroluminescent element
ES2475091T3 (es) 2009-04-16 2014-07-10 Centro Nacional De Investigaciones Oncol�Gicas (Cnio) Imidazopirazinas como inhibidores de proteína cinasas
WO2010138833A1 (en) * 2009-05-29 2010-12-02 Wyeth SUBSTITUTED IMIDAZO[1,5-a]QUINOXALINES AS INHIBITORS OF PHOSPHODIESTERASE 10
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
JP5709752B2 (ja) 2009-08-19 2015-04-30 出光興産株式会社 芳香族アミン誘導体及びそれを用いた有機エレクトロルミネッセンス素子
EP2493889B1 (en) 2009-10-30 2017-09-06 Janssen Pharmaceutica, N.V. IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2011059099A1 (ja) 2009-11-16 2011-05-19 出光興産株式会社 芳香族アミン誘導体及びそれを用いた有機エレクトロルミネッセンス素子
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
WO2012146644A1 (en) 2011-04-28 2012-11-01 Janssen Pharmaceutica Nv Salt of an inhibitor of phosphodiesterase 10 enzyme
AU2012277912B2 (en) 2011-06-27 2017-03-23 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
JP2014526453A (ja) 2011-09-09 2014-10-06 ハー・ルンドベック・アクチエゼルスカベット ピリジン化合物およびそれらの使用
WO2013034755A1 (en) 2011-09-09 2013-03-14 H. Lundbeck A/S Triazolopyrazine derivatives and their use for treating neurological and psychiatric disorders
MX362197B (es) 2012-07-09 2019-01-08 Janssen Pharmaceutica Nv Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
JP6247969B2 (ja) 2014-03-17 2017-12-13 本田技研工業株式会社 自動二輪車の排気装置

Also Published As

Publication number Publication date
EA027418B1 (ru) 2017-07-31
WO2013000924A1 (en) 2013-01-03
ES2575092T3 (es) 2016-06-24
AU2012277912A1 (en) 2013-12-19
EP2723744B1 (en) 2016-03-23
CN103619846A (zh) 2014-03-05
JP6115962B2 (ja) 2017-04-19
EP2723744A1 (en) 2014-04-30
MX344600B (es) 2016-12-20
US10604523B2 (en) 2020-03-31
US20140147386A1 (en) 2014-05-29
MX2013015201A (es) 2014-02-17
CN103619846B (zh) 2016-08-17
AU2012277912B2 (en) 2017-03-23
JP2014518234A (ja) 2014-07-28
BR112013033375B1 (pt) 2022-05-10
CA2838645C (en) 2020-03-10
BR112013033375A2 (pt) 2016-09-06
CA2838645A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
EA201490165A1 (ru) Производные 1-арил-4-метил-[1,2,4]триазоло[4,3-a]хиноксалина
EA201290878A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ
BRPI1012108B8 (pt) composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201290244A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10
MX2017005940A (es) Pyrazolo [1, 5-a] pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos.
EA201000552A1 (ru) Производные пирроло[2,3-d]пиримидина в качестве ингибиторов протеинкиназы в
EA201301184A1 (ru) Пиразоло[4,3-d]пиримидины, пригодные в качестве ингибиторов киназ
CL2008001364A1 (es) Uso de compuestos derivados de imidazol(1,2-b) piridazina y pirazolo(1,5-a) pirimidina inhibidores de tirosina quinasa pi-para tratar tumor benigno o maligno, entre otros; compuestos dereivados de imidazol(1,2-b)piridazina y pirazolo(1,5-a)pirimidina; composiciones farmaceuticas; y metodo de preparacion de compuestos.
MX348290B (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
MX2019011954A (es) Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b ][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas.
EA201270480A1 (ru) Новые соединения
EA201400707A1 (ru) Дизамещенные бензотиенил-пирролотриазины и их применение в качестве ингибиторов киназы рфрф
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
EA201290807A1 (ru) Циклобутановые и метилциклобутановые производные в качестве ингибиторов янус-киназы
ATE420883T1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
GB0606805D0 (en) Organic compounds
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
MX336332B (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MX362197B (es) Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
EA201290245A1 (ru) Радиоактивно меченные pde10 лиганды
EA200800920A1 (ru) Производные пиразоло[4,3-d]пиримидин-5-ила, применяемые в качестве ингибиторов фосфодиэстеразы 5 (pde5)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM